MCLA-129 / Betta Pharma, Merus  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MCLA-129 / Merus
METex14, NCT04868877 / 2021-000203-20: A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Recruiting
1/2
380
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
04/24
04/25
NCT04930432: Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Recruiting
1/2
400
RoW
MCLA-129
Betta Pharmaceuticals Co., Ltd.
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
06/24
06/25

Download Options